HLA typing in an IFN-alpha-induced scar sarcoidosis: possible pathogenetic and clinical implications.
Zampino
Maria Rosaria
MR
Corazza
Monica
M
Borghi
Alessandro
A
Marzola
Andrea
A
Virgili
Annarosa
A
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002921:Cicatrix / Q000139:chemically induced; D005260:Female; D005542:Forearm; D020022:Genetic Predisposition to Disease; D006680:HLA Antigens / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006650:Histocompatibility Testing; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins; D012507:Sarcoidosis / Q000139:chemically induced* / Q000235:genetics; D012871:Skin Diseases / Q000139:chemically induced* / Q000235:genetics
D000998:Antiviral Agents; D006680:HLA Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a